Lonza Sets New Mid-Term Targets and Confirms 2026 Outlook Ahead of Capital Markets Day

Swiss contract drug manufacturer Lonza announced new mid-term targets and reaffirmed its 2026 outlook on October 14, 2026, in anticipation of its capital markets day. The company stated that its third-quarter performance was consistent with expectations across all business areas. Lonza is progressing towards becoming a pure-play drug manufacturer, with the planned sale of its Capsules & Health Ingredients business expected to close by the end of 2026.